+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Companion Animal Arthritis Market By Companion Type, By Arthritis Type, By Treatment, By Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2021-2031

  • PDF Icon

    Report

  • 298 Pages
  • January 2023
  • Region: Global
  • Allied Market Research
  • ID: 5751206
The spread of arthritis is very common and more rapid among the companion animal population. This is the most common type of degenerative joint disease, generally known as osteoarthritis. Joints offer elastic connections and protective cushioning between bones.

Osteoarthritis causes bone growth inside joints, as well as fluid accumulation and cartilage loss. This can cause discomfort, joint deterioration, and reduced mobility over time for companion animals. A large number of medications are being introduced to the market to treat. These factors are anticipated to drive the companion animal arthritis market growth in the upcoming years. The rise in the prevalence of arthritis among pets such as dogs and cats which cause inflammation of joints is estimated to drive the companion animal arthritis market size.

The veterinary nonsteroidal anti-inflammatory drugs (NSAIDs) used for the treatment of arthritis in companion animals have a negative impact on the health of companion animals. For instance, in dogs and cats, veterinary NSAIDs can cause diarrhea, vomiting, and ulcers in the stomach and intestine. These factors are anticipated to hamper the companion animal arthritis market share during the forecast period.

The ongoing research activities for the development of therapeutic treatment for arthritis condition among animal is estimated to generate excellent growth opportunities in the market. For instance, research on companion dogs with naturally occurring illnesses inevitably provides information on how to reduce pain in companion pet dogs. Such knowledge, when paired with the safety data obtained by canine work, can serve as the foundation for a veterinary therapeutic development program. All these factors are projected to create several growth opportunities in the market.

The COVID-19 pandemic negatively impacted the companion animal arthritis market. The COVID-19 pandemic resulted in the establishment of strict lockdown and quarantine laws throughout the globe, which further restricted non-essential veterinary visits. Furthermore, the delay in medical operations has a significant impact on animal arthritis treatment. However, the introduction of the COVID-19 pandemic has increased pet adoption and foster applications, which is expected to help market expansion during the forecast period.

The key players profiled in this report include Zoetis, Virbac, Elanco, Boehringer Ingelheim International GmbH, Ceva, Dechra Pharmaceuticals PLC., Vetoquinol, NexGen Pharmaceuticals, and Norbrook.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the companion animal arthritis market analysis from 2021 to 2031 to identify the prevailing companion animal arthritis market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's Five Forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the companion animal arthritis market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global companion animal arthritis market trends, key players, market segments, application areas, and market growth Strategies.

Key Market Segments

By Companion Type

  • Dog
  • Cat
  • Horse

By Arthritis Type

  • Osteoarthritis
  • Rheumatoid Arthritis

By Treatment

  • Exercise
  • Medical

By Distribution Channel

  • Online Store
  • Pet Supply Store
  • Veterinary Hospitals and Clinics

By Region

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Rest of Europe
  • Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • Saudi Arabia
  • United Arab Emirates
  • South Africa
  • Rest of LAMEA

Key Market Players

  • Covetrus, Inc.
  • Zoetis
  • Elanco
  • Virbac
  • Dechra Pharmaceuticals plc
  • Vetoquinol Animal Health Pvt Ltd
  • Phibro Animal Health Corp
  • Boehringer Ingelheim GmbH
  • Bayer AG
  • Ceva Sante Animale

 

Please note:

  • Online Access price format is valid for 60 days access. Printing is not enabled.
  • PDF Single and Enterprise price formats enable printing.

 

Table of Contents

CHAPTER 1: INTRODUCTION
1.1.Report description
1.2.Key market segments
1.3.Key benefits to the stakeholders
1.4.Research Methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO Perspective

CHAPTER 3: MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.3.Porter’s five forces analysis
3.4.Market dynamics
3.4.1.Drivers
3.4.2.Restraints
3.4.3.Opportunities
3.5.COVID-19 Impact Analysis on the market
3.6.Value Chain Analysis
3.7.Key Regulation Analysis
3.8.Patent Landscape
3.9.Regulatory Guidelines
3.10.Market Share Analysis

CHAPTER 4: COMPANION ANIMAL ARTHRITIS MARKET, BY COMPANION TYPE
4.1 Overview
4.1.1 Market size and forecast
4.2. Dog
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market share analysis by country
4.3. Cat
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market share analysis by country
4.4. Horse
4.4.1 Key market trends, growth factors and opportunities
4.4.2 Market size and forecast, by region
4.4.3 Market share analysis by country

CHAPTER 5: COMPANION ANIMAL ARTHRITIS MARKET, BY ARTHRITIS TYPE
5.1 Overview
5.1.1 Market size and forecast
5.2. Osteoarthritis
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market share analysis by country
5.3. Rheumatoid Arthritis
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market share analysis by country

CHAPTER 6: COMPANION ANIMAL ARTHRITIS MARKET, BY TREATMENT
6.1 Overview
6.1.1 Market size and forecast
6.2. Exercise
6.2.1 Key market trends, growth factors and opportunities
6.2.2 Market size and forecast, by region
6.2.3 Market share analysis by country
6.3. Medical
6.3.1 Key market trends, growth factors and opportunities
6.3.2 Market size and forecast, by region
6.3.3 Market share analysis by country
6.4. Others
6.4.1 Key market trends, growth factors and opportunities
6.4.2 Market size and forecast, by region
6.4.3 Market share analysis by country

CHAPTER 7: COMPANION ANIMAL ARTHRITIS MARKET, BY DISTRIBUTION CHANNEL
7.1 Overview
7.1.1 Market size and forecast
7.2. Online Store
7.2.1 Key market trends, growth factors and opportunities
7.2.2 Market size and forecast, by region
7.2.3 Market share analysis by country
7.3. Pet Supply Store
7.3.1 Key market trends, growth factors and opportunities
7.3.2 Market size and forecast, by region
7.3.3 Market share analysis by country
7.4. Veterinary Hospitals and Clinics
7.4.1 Key market trends, growth factors and opportunities
7.4.2 Market size and forecast, by region
7.4.3 Market share analysis by country
7.5. Others
7.5.1 Key market trends, growth factors and opportunities
7.5.2 Market size and forecast, by region
7.5.3 Market share analysis by country

CHAPTER 8: COMPANION ANIMAL ARTHRITIS MARKET, BY REGION
8.1 Overview
8.1.1 Market size and forecast
8.2 North America
8.2.1 Key trends and opportunities
8.2.2 North America Market size and forecast, by Companion Type
8.2.3 North America Market size and forecast, by Arthritis Type
8.2.4 North America Market size and forecast, by Treatment
8.2.5 North America Market size and forecast, by Distribution Channel
8.2.6 North America Market size and forecast, by country
8.2.6.1 U.S.
8.2.6.1.1 Key market trends, growth factors and opportunities
8.2.6.1.2 Market size and forecast, by Companion Type
8.2.6.1.3 Market size and forecast, by Arthritis Type
8.2.6.1.4 Market size and forecast, by Treatment
8.2.6.1.5 Market size and forecast, by Distribution Channel
8.2.6.2 Canada
8.2.6.2.1 Key market trends, growth factors and opportunities
8.2.6.2.2 Market size and forecast, by Companion Type
8.2.6.2.3 Market size and forecast, by Arthritis Type
8.2.6.2.4 Market size and forecast, by Treatment
8.2.6.2.5 Market size and forecast, by Distribution Channel
8.2.6.3 Mexico
8.2.6.3.1 Key market trends, growth factors and opportunities
8.2.6.3.2 Market size and forecast, by Companion Type
8.2.6.3.3 Market size and forecast, by Arthritis Type
8.2.6.3.4 Market size and forecast, by Treatment
8.2.6.3.5 Market size and forecast, by Distribution Channel
8.3 Europe
8.3.1 Key trends and opportunities
8.3.2 Europe Market size and forecast, by Companion Type
8.3.3 Europe Market size and forecast, by Arthritis Type
8.3.4 Europe Market size and forecast, by Treatment
8.3.5 Europe Market size and forecast, by Distribution Channel
8.3.6 Europe Market size and forecast, by country
8.3.6.1 Germany
8.3.6.1.1 Key market trends, growth factors and opportunities
8.3.6.1.2 Market size and forecast, by Companion Type
8.3.6.1.3 Market size and forecast, by Arthritis Type
8.3.6.1.4 Market size and forecast, by Treatment
8.3.6.1.5 Market size and forecast, by Distribution Channel
8.3.6.2 UK
8.3.6.2.1 Key market trends, growth factors and opportunities
8.3.6.2.2 Market size and forecast, by Companion Type
8.3.6.2.3 Market size and forecast, by Arthritis Type
8.3.6.2.4 Market size and forecast, by Treatment
8.3.6.2.5 Market size and forecast, by Distribution Channel
8.3.6.3 France
8.3.6.3.1 Key market trends, growth factors and opportunities
8.3.6.3.2 Market size and forecast, by Companion Type
8.3.6.3.3 Market size and forecast, by Arthritis Type
8.3.6.3.4 Market size and forecast, by Treatment
8.3.6.3.5 Market size and forecast, by Distribution Channel
8.3.6.4 Spain
8.3.6.4.1 Key market trends, growth factors and opportunities
8.3.6.4.2 Market size and forecast, by Companion Type
8.3.6.4.3 Market size and forecast, by Arthritis Type
8.3.6.4.4 Market size and forecast, by Treatment
8.3.6.4.5 Market size and forecast, by Distribution Channel
8.3.6.5 Italy
8.3.6.5.1 Key market trends, growth factors and opportunities
8.3.6.5.2 Market size and forecast, by Companion Type
8.3.6.5.3 Market size and forecast, by Arthritis Type
8.3.6.5.4 Market size and forecast, by Treatment
8.3.6.5.5 Market size and forecast, by Distribution Channel
8.3.6.6 Rest of Europe
8.3.6.6.1 Key market trends, growth factors and opportunities
8.3.6.6.2 Market size and forecast, by Companion Type
8.3.6.6.3 Market size and forecast, by Arthritis Type
8.3.6.6.4 Market size and forecast, by Treatment
8.3.6.6.5 Market size and forecast, by Distribution Channel
8.4 Asia-Pacific
8.4.1 Key trends and opportunities
8.4.2 Asia-Pacific Market size and forecast, by Companion Type
8.4.3 Asia-Pacific Market size and forecast, by Arthritis Type
8.4.4 Asia-Pacific Market size and forecast, by Treatment
8.4.5 Asia-Pacific Market size and forecast, by Distribution Channel
8.4.6 Asia-Pacific Market size and forecast, by country
8.4.6.1 China
8.4.6.1.1 Key market trends, growth factors and opportunities
8.4.6.1.2 Market size and forecast, by Companion Type
8.4.6.1.3 Market size and forecast, by Arthritis Type
8.4.6.1.4 Market size and forecast, by Treatment
8.4.6.1.5 Market size and forecast, by Distribution Channel
8.4.6.2 Japan
8.4.6.2.1 Key market trends, growth factors and opportunities
8.4.6.2.2 Market size and forecast, by Companion Type
8.4.6.2.3 Market size and forecast, by Arthritis Type
8.4.6.2.4 Market size and forecast, by Treatment
8.4.6.2.5 Market size and forecast, by Distribution Channel
8.4.6.3 India
8.4.6.3.1 Key market trends, growth factors and opportunities
8.4.6.3.2 Market size and forecast, by Companion Type
8.4.6.3.3 Market size and forecast, by Arthritis Type
8.4.6.3.4 Market size and forecast, by Treatment
8.4.6.3.5 Market size and forecast, by Distribution Channel
8.4.6.4 South Korea
8.4.6.4.1 Key market trends, growth factors and opportunities
8.4.6.4.2 Market size and forecast, by Companion Type
8.4.6.4.3 Market size and forecast, by Arthritis Type
8.4.6.4.4 Market size and forecast, by Treatment
8.4.6.4.5 Market size and forecast, by Distribution Channel
8.4.6.5 Australia
8.4.6.5.1 Key market trends, growth factors and opportunities
8.4.6.5.2 Market size and forecast, by Companion Type
8.4.6.5.3 Market size and forecast, by Arthritis Type
8.4.6.5.4 Market size and forecast, by Treatment
8.4.6.5.5 Market size and forecast, by Distribution Channel
8.4.6.6 Rest of Asia-Pacific
8.4.6.6.1 Key market trends, growth factors and opportunities
8.4.6.6.2 Market size and forecast, by Companion Type
8.4.6.6.3 Market size and forecast, by Arthritis Type
8.4.6.6.4 Market size and forecast, by Treatment
8.4.6.6.5 Market size and forecast, by Distribution Channel
8.5 LAMEA
8.5.1 Key trends and opportunities
8.5.2 LAMEA Market size and forecast, by Companion Type
8.5.3 LAMEA Market size and forecast, by Arthritis Type
8.5.4 LAMEA Market size and forecast, by Treatment
8.5.5 LAMEA Market size and forecast, by Distribution Channel
8.5.6 LAMEA Market size and forecast, by country
8.5.6.1 Brazil
8.5.6.1.1 Key market trends, growth factors and opportunities
8.5.6.1.2 Market size and forecast, by Companion Type
8.5.6.1.3 Market size and forecast, by Arthritis Type
8.5.6.1.4 Market size and forecast, by Treatment
8.5.6.1.5 Market size and forecast, by Distribution Channel
8.5.6.2 Saudi Arabia
8.5.6.2.1 Key market trends, growth factors and opportunities
8.5.6.2.2 Market size and forecast, by Companion Type
8.5.6.2.3 Market size and forecast, by Arthritis Type
8.5.6.2.4 Market size and forecast, by Treatment
8.5.6.2.5 Market size and forecast, by Distribution Channel
8.5.6.3 United Arab Emirates
8.5.6.3.1 Key market trends, growth factors and opportunities
8.5.6.3.2 Market size and forecast, by Companion Type
8.5.6.3.3 Market size and forecast, by Arthritis Type
8.5.6.3.4 Market size and forecast, by Treatment
8.5.6.3.5 Market size and forecast, by Distribution Channel
8.5.6.4 South Africa
8.5.6.4.1 Key market trends, growth factors and opportunities
8.5.6.4.2 Market size and forecast, by Companion Type
8.5.6.4.3 Market size and forecast, by Arthritis Type
8.5.6.4.4 Market size and forecast, by Treatment
8.5.6.4.5 Market size and forecast, by Distribution Channel
8.5.6.5 Rest of LAMEA
8.5.6.5.1 Key market trends, growth factors and opportunities
8.5.6.5.2 Market size and forecast, by Companion Type
8.5.6.5.3 Market size and forecast, by Arthritis Type
8.5.6.5.4 Market size and forecast, by Treatment
8.5.6.5.5 Market size and forecast, by Distribution Channel

CHAPTER 9: COMPETITIVE LANDSCAPE
9.1. Introduction
9.2. Top winning strategies
9.3. Product Mapping of Top 10 Player
9.4. Competitive Dashboard
9.5. Competitive Heatmap
9.6. Top player positioning, 2021

CHAPTER 10: COMPANY PROFILES
10.1 Covetrus, Inc.
10.1.1 Company overview
10.1.2 Key Executives
10.1.3 Company snapshot
10.1.4 Operating business segments
10.1.5 Product portfolio
10.1.6 Business performance
10.1.7 Key strategic moves and developments
10.2 Zoetis
10.2.1 Company overview
10.2.2 Key Executives
10.2.3 Company snapshot
10.2.4 Operating business segments
10.2.5 Product portfolio
10.2.6 Business performance
10.2.7 Key strategic moves and developments
10.3 Elanco
10.3.1 Company overview
10.3.2 Key Executives
10.3.3 Company snapshot
10.3.4 Operating business segments
10.3.5 Product portfolio
10.3.6 Business performance
10.3.7 Key strategic moves and developments
10.4 Virbac
10.4.1 Company overview
10.4.2 Key Executives
10.4.3 Company snapshot
10.4.4 Operating business segments
10.4.5 Product portfolio
10.4.6 Business performance
10.4.7 Key strategic moves and developments
10.5 Dechra Pharmaceuticals plc
10.5.1 Company overview
10.5.2 Key Executives
10.5.3 Company snapshot
10.5.4 Operating business segments
10.5.5 Product portfolio
10.5.6 Business performance
10.5.7 Key strategic moves and developments
10.6 Vetoquinol Animal Health Pvt Ltd
10.6.1 Company overview
10.6.2 Key Executives
10.6.3 Company snapshot
10.6.4 Operating business segments
10.6.5 Product portfolio
10.6.6 Business performance
10.6.7 Key strategic moves and developments
10.7 Phibro Animal Health Corp
10.7.1 Company overview
10.7.2 Key Executives
10.7.3 Company snapshot
10.7.4 Operating business segments
10.7.5 Product portfolio
10.7.6 Business performance
10.7.7 Key strategic moves and developments
10.8 Boehringer Ingelheim GmbH
10.8.1 Company overview
10.8.2 Key Executives
10.8.3 Company snapshot
10.8.4 Operating business segments
10.8.5 Product portfolio
10.8.6 Business performance
10.8.7 Key strategic moves and developments
10.9 Bayer AG
10.9.1 Company overview
10.9.2 Key Executives
10.9.3 Company snapshot
10.9.4 Operating business segments
10.9.5 Product portfolio
10.9.6 Business performance
10.9.7 Key strategic moves and developments
10.10 Ceva Sante Animale
10.10.1 Company overview
10.10.2 Key Executives
10.10.3 Company snapshot
10.10.4 Operating business segments
10.10.5 Product portfolio
10.10.6 Business performance
10.10.7 Key strategic moves and developments

List of Tables
Table 1. Global Companion Animal Arthritis Market, by Companion Type, 2021-2031 (Revenue, $Million)
Table 2. Companion Animal Arthritis Market for Dog, by Region, 2021-2031 (Revenue, $Million)
Table 3. Companion Animal Arthritis Market for Cat, by Region, 2021-2031 (Revenue, $Million)
Table 4. Companion Animal Arthritis Market for Horse, by Region, 2021-2031 (Revenue, $Million)
Table 5. Global Companion Animal Arthritis Market, by Arthritis Type, 2021-2031 (Revenue, $Million)
Table 6. Companion Animal Arthritis Market for Osteoarthritis, by Region, 2021-2031 (Revenue, $Million)
Table 7. Companion Animal Arthritis Market for Rheumatoid Arthritis, by Region, 2021-2031 (Revenue, $Million)
Table 8. Global Companion Animal Arthritis Market, by Treatment, 2021-2031 (Revenue, $Million)
Table 9. Companion Animal Arthritis Market for Exercise, by Region, 2021-2031 (Revenue, $Million)
Table 10. Companion Animal Arthritis Market for Medical, by Region, 2021-2031 (Revenue, $Million)
Table 11. Companion Animal Arthritis Market for Others, by Region, 2021-2031 (Revenue, $Million)
Table 12. Global Companion Animal Arthritis Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 13. Companion Animal Arthritis Market for Online Store, by Region, 2021-2031 (Revenue, $Million)
Table 14. Companion Animal Arthritis Market for Pet Supply Store, by Region, 2021-2031 (Revenue, $Million)
Table 15. Companion Animal Arthritis Market for Veterinary Hospitals and Clinics, by Region, 2021-2031 (Revenue, $Million)
Table 16. Companion Animal Arthritis Market for Others, by Region, 2021-2031 (Revenue, $Million)
Table 17. Companion Animal Arthritis Market, by Region, 2021-2031 (Revenue, $Million)
Table 18. North America Companion Animal Arthritis Market, by Companion Type, 2021-2031 (Revenue, $Million)
Table 19. North America Companion Animal Arthritis Market, by Arthritis Type, 2021-2031 (Revenue, $Million)
Table 20. North America Companion Animal Arthritis Market, by Treatment, 2021-2031 (Revenue, $Million)
Table 21. North America Companion Animal Arthritis Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 22. North America Companion Animal Arthritis Market, by Country, 2021-2031 (Revenue, $Million)
Table 23. U.S. Companion Animal Arthritis Market, by Companion Type, 2021-2031 (Revenue, $Million)
Table 24. U.S. Companion Animal Arthritis Market, by Arthritis Type, 2021-2031 (Revenue, $Million)
Table 25. U.S. Companion Animal Arthritis Market, by Treatment, 2021-2031 (Revenue, $Million)
Table 26. U.S. Companion Animal Arthritis Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 27. Canada Companion Animal Arthritis Market, by Companion Type, 2021-2031 (Revenue, $Million)
Table 28. Canada Companion Animal Arthritis Market, by Arthritis Type, 2021-2031 (Revenue, $Million)
Table 29. Canada Companion Animal Arthritis Market, by Treatment, 2021-2031 (Revenue, $Million)
Table 30. Canada Companion Animal Arthritis Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 31. Mexico Companion Animal Arthritis Market, by Companion Type, 2021-2031 (Revenue, $Million)
Table 32. Mexico Companion Animal Arthritis Market, by Arthritis Type, 2021-2031 (Revenue, $Million)
Table 33. Mexico Companion Animal Arthritis Market, by Treatment, 2021-2031 (Revenue, $Million)
Table 34. Mexico Companion Animal Arthritis Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 35. Europe Companion Animal Arthritis Market, by Companion Type, 2021-2031 (Revenue, $Million)
Table 36. Europe Companion Animal Arthritis Market, by Arthritis Type, 2021-2031 (Revenue, $Million)
Table 37. Europe Companion Animal Arthritis Market, by Treatment, 2021-2031 (Revenue, $Million)
Table 38. Europe Companion Animal Arthritis Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 39. Europe Companion Animal Arthritis Market, by Country, 2021-2031 (Revenue, $Million)
Table 40. Germany Companion Animal Arthritis Market, by Companion Type, 2021-2031 (Revenue, $Million)
Table 41. Germany Companion Animal Arthritis Market, by Arthritis Type, 2021-2031 (Revenue, $Million)
Table 42. Germany Companion Animal Arthritis Market, by Treatment, 2021-2031 (Revenue, $Million)
Table 43. Germany Companion Animal Arthritis Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 44. UK Companion Animal Arthritis Market, by Companion Type, 2021-2031 (Revenue, $Million)
Table 45. UK Companion Animal Arthritis Market, by Arthritis Type, 2021-2031 (Revenue, $Million)
Table 46. UK Companion Animal Arthritis Market, by Treatment, 2021-2031 (Revenue, $Million)
Table 47. UK Companion Animal Arthritis Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 48. France Companion Animal Arthritis Market, by Companion Type, 2021-2031 (Revenue, $Million)
Table 49. France Companion Animal Arthritis Market, by Arthritis Type, 2021-2031 (Revenue, $Million)
Table 50. France Companion Animal Arthritis Market, by Treatment, 2021-2031 (Revenue, $Million)
Table 51. France Companion Animal Arthritis Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 52. Spain Companion Animal Arthritis Market, by Companion Type, 2021-2031 (Revenue, $Million)
Table 53. Spain Companion Animal Arthritis Market, by Arthritis Type, 2021-2031 (Revenue, $Million)
Table 54. Spain Companion Animal Arthritis Market, by Treatment, 2021-2031 (Revenue, $Million)
Table 55. Spain Companion Animal Arthritis Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 56. Italy Companion Animal Arthritis Market, by Companion Type, 2021-2031 (Revenue, $Million)
Table 57. Italy Companion Animal Arthritis Market, by Arthritis Type, 2021-2031 (Revenue, $Million)
Table 58. Italy Companion Animal Arthritis Market, by Treatment, 2021-2031 (Revenue, $Million)
Table 59. Italy Companion Animal Arthritis Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 60. Rest of Europe Companion Animal Arthritis Market, by Companion Type, 2021-2031 (Revenue, $Million)
Table 61. Rest of Europe Companion Animal Arthritis Market, by Arthritis Type, 2021-2031 (Revenue, $Million)
Table 62. Rest of Europe Companion Animal Arthritis Market, by Treatment, 2021-2031 (Revenue, $Million)
Table 63. Rest of Europe Companion Animal Arthritis Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 64. Asia-Pacific Companion Animal Arthritis Market, by Companion Type, 2021-2031 (Revenue, $Million)
Table 65. Asia-Pacific Companion Animal Arthritis Market, by Arthritis Type, 2021-2031 (Revenue, $Million)
Table 66. Asia-Pacific Companion Animal Arthritis Market, by Treatment, 2021-2031 (Revenue, $Million)
Table 67. Asia-Pacific Companion Animal Arthritis Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 68. Asia-Pacific Companion Animal Arthritis Market, by Country, 2021-2031 (Revenue, $Million)
Table 69. China Companion Animal Arthritis Market, by Companion Type, 2021-2031 (Revenue, $Million)
Table 70. China Companion Animal Arthritis Market, by Arthritis Type, 2021-2031 (Revenue, $Million)
Table 71. China Companion Animal Arthritis Market, by Treatment, 2021-2031 (Revenue, $Million)
Table 72. China Companion Animal Arthritis Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 73. Japan Companion Animal Arthritis Market, by Companion Type, 2021-2031 (Revenue, $Million)
Table 74. Japan Companion Animal Arthritis Market, by Arthritis Type, 2021-2031 (Revenue, $Million)
Table 75. Japan Companion Animal Arthritis Market, by Treatment, 2021-2031 (Revenue, $Million)
Table 76. Japan Companion Animal Arthritis Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 77. India Companion Animal Arthritis Market, by Companion Type, 2021-2031 (Revenue, $Million)
Table 78. India Companion Animal Arthritis Market, by Arthritis Type, 2021-2031 (Revenue, $Million)
Table 79. India Companion Animal Arthritis Market, by Treatment, 2021-2031 (Revenue, $Million)
Table 80. India Companion Animal Arthritis Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 81. South Korea Companion Animal Arthritis Market, by Companion Type, 2021-2031 (Revenue, $Million)
Table 82. South Korea Companion Animal Arthritis Market, by Arthritis Type, 2021-2031 (Revenue, $Million)
Table 83. South Korea Companion Animal Arthritis Market, by Treatment, 2021-2031 (Revenue, $Million)
Table 84. South Korea Companion Animal Arthritis Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 85. Australia Companion Animal Arthritis Market, by Companion Type, 2021-2031 (Revenue, $Million)
Table 86. Australia Companion Animal Arthritis Market, by Arthritis Type, 2021-2031 (Revenue, $Million)
Table 87. Australia Companion Animal Arthritis Market, by Treatment, 2021-2031 (Revenue, $Million)
Table 88. Australia Companion Animal Arthritis Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 89. Rest of Asia-Pacific Companion Animal Arthritis Market, by Companion Type, 2021-2031 (Revenue, $Million)
Table 90. Rest of Asia-Pacific Companion Animal Arthritis Market, by Arthritis Type, 2021-2031 (Revenue, $Million)
Table 91. Rest of Asia-Pacific Companion Animal Arthritis Market, by Treatment, 2021-2031 (Revenue, $Million)
Table 92. Rest of Asia-Pacific Companion Animal Arthritis Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 93. LAMEA Companion Animal Arthritis Market, by Companion Type, 2021-2031 (Revenue, $Million)
Table 94. LAMEA Companion Animal Arthritis Market, by Arthritis Type, 2021-2031 (Revenue, $Million)
Table 95. LAMEA Companion Animal Arthritis Market, by Treatment, 2021-2031 (Revenue, $Million)
Table 96. LAMEA Companion Animal Arthritis Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 97. LAMEA Companion Animal Arthritis Market, by Country, 2021-2031 (Revenue, $Million)
Table 98. Brazil Companion Animal Arthritis Market, by Companion Type, 2021-2031 (Revenue, $Million)
Table 99. Brazil Companion Animal Arthritis Market, by Arthritis Type, 2021-2031 (Revenue, $Million)
Table 100. Brazil Companion Animal Arthritis Market, by Treatment, 2021-2031 (Revenue, $Million)
Table 101. Brazil Companion Animal Arthritis Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 102. Saudi Arabia Companion Animal Arthritis Market, by Companion Type, 2021-2031 (Revenue, $Million)
Table 103. Saudi Arabia Companion Animal Arthritis Market, by Arthritis Type, 2021-2031 (Revenue, $Million)
Table 104. Saudi Arabia Companion Animal Arthritis Market, by Treatment, 2021-2031 (Revenue, $Million)
Table 105. Saudi Arabia Companion Animal Arthritis Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 106. United Arab Emirates Companion Animal Arthritis Market, by Companion Type, 2021-2031 (Revenue, $Million)
Table 107. United Arab Emirates Companion Animal Arthritis Market, by Arthritis Type, 2021-2031 (Revenue, $Million)
Table 108. United Arab Emirates Companion Animal Arthritis Market, by Treatment, 2021-2031 (Revenue, $Million)
Table 109. United Arab Emirates Companion Animal Arthritis Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 110. South Africa Companion Animal Arthritis Market, by Companion Type, 2021-2031 (Revenue, $Million)
Table 111. South Africa Companion Animal Arthritis Market, by Arthritis Type, 2021-2031 (Revenue, $Million)
Table 112. South Africa Companion Animal Arthritis Market, by Treatment, 2021-2031 (Revenue, $Million)
Table 113. South Africa Companion Animal Arthritis Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 114. Rest of LAMEA Companion Animal Arthritis Market, by Companion Type, 2021-2031 (Revenue, $Million)
Table 115. Rest of LAMEA Companion Animal Arthritis Market, by Arthritis Type, 2021-2031 (Revenue, $Million)
Table 116. Rest of LAMEA Companion Animal Arthritis Market, by Treatment, 2021-2031 (Revenue, $Million)
Table 117. Rest of LAMEA Companion Animal Arthritis Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 118. Covetrus, Inc.: Key Executives
Table 119. Covetrus, Inc.: Company Snapshot
Table 120. Covetrus, Inc.: Operating Segments
Table 121. Covetrus, Inc.: Product Portfolio
Table 122. Covetrus, Inc.: Net Sales
Table 123. Covetrus, Inc.: Key Strategies
Table 124. Zoetis: Key Executives
Table 125. Zoetis: Company Snapshot
Table 126. Zoetis: Operating Segments
Table 127. Zoetis: Product Portfolio
Table 128. Zoetis: Net Sales
Table 129. Zoetis: Key Strategies
Table 130. Elanco: Key Executives
Table 131. Elanco: Company Snapshot
Table 132. Elanco: Operating Segments
Table 133. Elanco: Product Portfolio
Table 134. Elanco: Net Sales
Table 135. Elanco: Key Strategies
Table 136. Virbac: Key Executives
Table 137. Virbac: Company Snapshot
Table 138. Virbac: Operating Segments
Table 139. Virbac: Product Portfolio
Table 140. Virbac: Net Sales
Table 141. Virbac: Key Strategies
Table 142. Dechra Pharmaceuticals PLC: Key Executives
Table 143. Dechra Pharmaceuticals PLC: Company Snapshot
Table 144. Dechra Pharmaceuticals PLC: Operating Segments
Table 145. Dechra Pharmaceuticals PLC: Product Portfolio
Table 146. Dechra Pharmaceuticals PLC: Net Sales
Table 147. Dechra Pharmaceuticals PLC: Key Strategies
Table 148. Vetoquinol Animal Health Pvt Ltd.: Key Executives
Table 149. Vetoquinol Animal Health Pvt Ltd.: Company Snapshot
Table 150. Vetoquinol Animal Health Pvt Ltd.: Operating Segments
Table 151. Vetoquinol Animal Health Pvt Ltd.: Product Portfolio
Table 152. Vetoquinol Animal Health Pvt Ltd.: Net Sales
Table 153. Vetoquinol Animal Health Pvt Ltd.: Key Strategies
Table 154. Phibro Animal Health Corp: Key Executives
Table 155. Phibro Animal Health Corp: Company Snapshot
Table 156. Phibro Animal Health Corp: Operating Segments
Table 157. Phibro Animal Health Corp: Product Portfolio
Table 158. Phibro Animal Health Corp: Net Sales
Table 159. Phibro Animal Health Corp: Key Strategies
Table 160. Boehringer Ingelheim GmbH: Key Executives
Table 161. Boehringer Ingelheim GmbH: Company Snapshot
Table 162. Boehringer Ingelheim GmbH: Operating Segments
Table 163. Boehringer Ingelheim GmbH: Product Portfolio
Table 164. Boehringer Ingelheim GmbH: Net Sales
Table 165. Boehringer Ingelheim GmbH: Key Strategies
Table 166. Bayer AG: Key Executives
Table 167. Bayer AG: Company Snapshot
Table 168. Bayer AG: Operating Segments
Table 169. Bayer AG: Product Portfolio
Table 170. Bayer AG: Net Sales
Table 171. Bayer AG: Key Strategies
Table 172. Ceva Sante Animale: Key Executives
Table 173. Ceva Sante Animale: Company Snapshot
Table 174. Ceva Sante Animale: Operating Segments
Table 175. Ceva Sante Animale: Product Portfolio
Table 176. Ceva Sante Animale: Net Sales
Table 177. Ceva Sante Animale: Key Strategies

List of Figures
Figure 1. Segmentation of Companion Animal Arthritis Market,2021-2031
Figure 2. Companion Animal Arthritis Market,2021-2031
Figure 3. Top Investment Pockets, by Region
Figure 4. Porter Five-1
Figure 5. Porter Five-2
Figure 6. Porter Five-3
Figure 7. Porter Five-4
Figure 8. Porter Five-5
Figure 9. Companion Animal Arthritis Market:Drivers, Restraints and Opportunities
Figure 10. Value Chain Analysis
Figure 11. Key Regulation Analysis
Figure 12. Patent Analysis by Company
Figure 13. Patent Analysis by Country
Figure 14. Regulatory Guidelines
Figure 15. Market Share Analysis
Figure 16. Companion Animal Arthritis Market,By Companion Type,2021(%)
Figure 17. Comparative Share Analysis of Dog Companion Animal Arthritis Market, 2021 and 2031(%)
Figure 18. Comparative Share Analysis of Cat Companion Animal Arthritis Market, 2021 and 2031(%)
Figure 19. Comparative Share Analysis of Horse Companion Animal Arthritis Market, 2021 and 2031(%)
Figure 20. Companion Animal Arthritis Market,By Arthritis Type,2021(%)
Figure 21. Comparative Share Analysis of Osteoarthritis Companion Animal Arthritis Market, 2021 and 2031(%)
Figure 22. Comparative Share Analysis of Rheumatoid Arthritis Companion Animal Arthritis Market, 2021 and 2031(%)
Figure 23. Companion Animal Arthritis Market,By Treatment,2021(%)
Figure 24. Comparative Share Analysis of Exercise Companion Animal Arthritis Market, 2021 and 2031(%)
Figure 25. Comparative Share Analysis of Medical Companion Animal Arthritis Market, 2021 and 2031(%)
Figure 26. Comparative Share Analysis of Others Companion Animal Arthritis Market, 2021 and 2031(%)
Figure 27. Companion Animal Arthritis Market,By Distribution Channel,2021(%)
Figure 28. Comparative Share Analysis of Online Store Companion Animal Arthritis Market, 2021 and 2031(%)
Figure 29. Comparative Share Analysis of Pet Supply Store Companion Animal Arthritis Market, 2021 and 2031(%)
Figure 30. Comparative Share Analysis of Veterinary Hospitals and Clinics Companion Animal Arthritis Market, 2021 and 2031(%)
Figure 31. Comparative Share Analysis of Others Companion Animal Arthritis Market, 2021 and 2031(%)
Figure 32. Companion Animal Arthritis Market by Region,2021
Figure 33. U.S. Companion Animal Arthritis Market,2021-2031($Million)
Figure 34. Canada Companion Animal Arthritis Market,2021-2031($Million)
Figure 35. Mexico Companion Animal Arthritis Market,2021-2031($Million)
Figure 36. Germany Companion Animal Arthritis Market,2021-2031($Million)
Figure 37. UK Companion Animal Arthritis Market,2021-2031($Million)
Figure 38. France Companion Animal Arthritis Market,2021-2031($Million)
Figure 39. Spain Companion Animal Arthritis Market,2021-2031($Million)
Figure 40. Italy Companion Animal Arthritis Market,2021-2031($Million)
Figure 41. Rest of Europe Companion Animal Arthritis Market,2021-2031($Million)
Figure 42. China Companion Animal Arthritis Market,2021-2031($Million)
Figure 43. Japan Companion Animal Arthritis Market,2021-2031($Million)
Figure 44. India Companion Animal Arthritis Market,2021-2031($Million)
Figure 45. South Korea Companion Animal Arthritis Market,2021-2031($Million)
Figure 46. Australia Companion Animal Arthritis Market,2021-2031($Million)
Figure 47. Rest of Asia-Pacific Companion Animal Arthritis Market,2021-2031($Million)
Figure 48. Brazil Companion Animal Arthritis Market,2021-2031($Million)
Figure 49. Saudi Arabia Companion Animal Arthritis Market,2021-2031($Million)
Figure 50. United Arab Emirates Companion Animal Arthritis Market,2021-2031($Million)
Figure 51. South Africa Companion Animal Arthritis Market,2021-2031($Million)
Figure 52. Rest of LAMEA Companion Animal Arthritis Market,2021-2031($Million)
Figure 53. Top Winning Strategies, by Year
Figure 54. Top Winning Strategies, by Development
Figure 55. Top Winning Strategies, by Company
Figure 56. Product Mapping of Top 10 Players
Figure 57. Competitive Dashboard
Figure 58. Competitive Heatmap of Top 10 Key Players
Figure 59. Top Player Positioning, 2021
Figure 60. Covetrus, Inc..: Net Sales ($Million)
Figure 61. Zoetis.: Net Sales ($Million)
Figure 62. Elanco.: Net Sales ($Million)
Figure 63. Virbac.: Net Sales ($Million)
Figure 64. Dechra Pharmaceuticals PLC.: Net Sales ($Million)
Figure 65. Vetoquinol Animal Health Pvt Ltd.: Net Sales ($Million)
Figure 66. Phibro Animal Health Corp.: Net Sales ($Million)
Figure 67. Boehringer Ingelheim GmbH.: Net Sales ($Million)
Figure 68. Bayer AG.: Net Sales ($Million)
Figure 69. Ceva Sante Animale.: Net Sales ($Million)

Executive Summary

According to the report titled, 'Companion Animal Arthritis Market,' the companion animal arthritis market was valued at $2.9 billion in 2021, and is estimated to reach $5.5 billion by 2031, growing at a CAGR of 7% from 2022 to 2031.

Arthritis is a common condition among companion animals such as dogs, cats, and horses. Arthritis in dogs is caused due to age-related cartilage damage or joint injury. This condition is usually treated with non-steroidal anti-inflammatories, nutritional supplements, and weight management.

Key factors driving the growth of the companion animal arthritis market include a rise in pet adoption and several awareness programs launched by governments. Many studies have revealed that having a dog nearby encourages human socialization. There is a rise in companion animal populace as they lower stress and help youngsters participate in social activities and develop their compassion and self-esteem. Governments of various countries across the globe are also initiating supporting awareness programs. Therefore, rising awareness regarding companion animals is projected to drive the market growth during the forecast period.

Rise in the popularity of companion animal arthritis in natural OTC treatments owing to its effectiveness in reducing inflammation to generate excellent opportunities for the market players. It has been demonstrated that certain over-the-counter supplements are effective in protecting joint health and reducing inflammation. These supplements include omega-3 fatty acids, glucosamine, chondroitin, MSM, creatine, and antioxidants. All these factors are projected to create numerous growth prospects for the key players operating in the market.

The companion animal arthritis market is segmented on the basis of companion type, arthritis type, treatment, distribution channel, and region. On the basis of companion type, the market is classified into dog, cat, and horse. On the basis of arthritis type, it is divided into osteoarthritis and rheumatoid arthritis. On the basis of treatment, it is classified into exercise, medical, and others. On the basis of distribution channel, it is divided into online store, pet supply store, veterinary hospitals and clinics, and others. Region wise, it is analyzed across North America (the U.S., Canada, and Mexico), Europe (the UK, Germany, Italy, France, Spain, and rest of Europe), Asia-Pacific (China, India, Japan, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, United Arab Emirates, South Africa, and rest of LAMEA).

The key players profiled in the study include Zoetis, Virbac, Elanco, Boehringer Ingelheim International GmbH, Ceva, Dechra Pharmaceuticals PLC., Vetoquinol, NexGen Pharmaceuticals, and Norbrook. The major players in the market have been actively engaged in the adoption of various Strategies such as acquisition, product launch, and expansion to remain competitive and gain an advantage over the competitors in the market. For instance, in January 2022, an injection of a monoclonal antibody called Solentia by Zoetis received Food and Drug Administration (FDA) approval in the U.S.

Key Market Insights

By companion type, the dog segment was the highest revenue contributor to the market. However, the cat segment is estimated to be the fastest growing during the forecast period.

By arthritis type, the osteoarthritis segment was the highest revenue contributor to the market. However, the rheumatoid segment is expected to be the fastest growing during the forecast period.

Based on treatment, the medical segment was the highest revenue contributor to the market in 2021. However, the exercise segment is expected to be the fastest growing during the forecast years.

Based on distribution channel, the pet supply segment was the highest revenue contributor to the market in 2021. However, the veterinary hospitals and clinics segment is expected to be the fastest growing during the forecast years.

Based on region, North America was the highest revenue contributor to the market in 2021 accounting for a market size of $248.7 million

Companies Mentioned

  • Covetrus, Inc.
  • Zoetis
  • Elanco
  • Virbac
  • Dechra Pharmaceuticals plc
  • Vetoquinol Animal Health Pvt Ltd
  • Phibro Animal Health Corp
  • Boehringer Ingelheim GmbH
  • Bayer AG
  • Ceva Sante Animale

Methodology

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.

Loading
LOADING...